. Author manuscript; available in PMC: 2015 Jan 1.

Published in final edited form as: J Am Acad Child Adolesc Psychiatry. 2013 Nov 18;53(1):47–60.e1. doi: 10.1016/j.jaac.2013.09.022

Table 3.

Adverse Events Reported In Weeks 4 to 9 for Nine or More Subjects Per Group

	basic (n=80)		Augmented (n=73)
Variable	n	%	n	%	p value^a
Trouble falling asleep	29	36.3	14	19.2	0.0205
Rhinorrhea	14	17.5	11	15.0	0.8273
Cough	20	25.0	14	19.2	0.4394
Appetite decrease	19	23.8	9	12.3	0.0935
Appetite increase	7	8.8	10	13.7	0.4412
Diarrhea	9	11.3	5	6.8	0.4088
Gastrointestinal discomfort	4	5.0	12	16.4	0.0322
Vomiting	6	7.5	10	13.7	0.2910
Sedation	20	25.0	16	21.9	0.7504
Headache	17	21.3	16	21.9	1.0000

Notes: Basic = parent training + stimulant + placebo ; Augmented = parent training + stimulant + risperidone. Sample size for each group excludes those who dropped out at or before Week 3. One subject within Basic treatment took medication between Week 3 and 4 but did not return for assessment, resulting in n=80.

Fisher's Exact Test used to compare incidence of adverse events between groups